Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
Allergy Asthma Clin Immunol. 2023 Jun 23;19(1):54.
doi: 10.1186/s13223-023-00805-3.
1 Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, L8N 3Z5, Canada.
2 Division of Infectious Diseases, Department of Medicine, Department of Biochemistry, Microbiology, and Immunology; Centre for Infection, Immunity and Inflammation, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, K1H 8M5, Canada.
3 Division of Allergy and Clinical Immunology, Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC, V6Z 1Y6, Canada.
4 Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, ON, N6A 5A5, Canada.
5 Department of Medicine, Dalhousie University, Halifax, NS, B3H 2Y9, Canada.
6 Chair of Toronto Allergists and Evidence Based Medical Educator, Toronto, ON, M5G 1E2, Canada.
7 Takeda Development Center Americas, Inc., Cambridge, MA, 02139, USA.